Eli Lilly and Company (LLY)

Key Updates

Eli Lilly surged 3.47% to $1,126.80 since the May 27th report, driven by CVS Caremark's decision to restore Zepbound coverage on its preferred drug list effective October 2026, with the newer oral formulation Foundayo receiving coverage from June 1st. This catalytic development propelled the stock toward record highs and restored the company's market capitalization above $1 trillion. The momentum extends the stock's recovery to +10.59% over five days and +28.92% over one month, representing a decisive reversal from the earlier 2026 weakness. The CVS formulary reinstatement addresses a critical competitive vulnerability that had previously allowed Novo Nordisk to capture market share during Zepbound's exclusion period.

Current Trend

Eli Lilly has established a robust uptrend with YTD gains of +4.85% and six-month performance of +4.77%, demonstrating resilience following the sharp recovery from April lows. The stock decisively broke through the $1,000 psychological resistance in mid-May and has now consolidated above $1,100, approaching the all-time high of $1,130.90 reached intraday on May 28th. The recent five-day surge of +10.59% represents the strongest weekly performance in months, supported by significant volume expansion. The one-month gain of +28.92% reflects sustained institutional accumulation following the Q1 earnings beat and subsequent positive catalysts. Near-term resistance stands at the $1,131 intraday high, while support has solidified at the $1,067-$1,089 range established in late May.

Investment Thesis

The investment thesis centers on Eli Lilly's commanding position in the high-growth GLP-1 obesity and diabetes markets, with Zepbound and Mounjaro driving exceptional revenue expansion despite pricing pressures. The company demonstrated pricing power resilience in Q1 2026, offsetting a 7% U.S. price decline with 49% volume growth to achieve 56% revenue growth to $19.8 billion. Strategic diversification through approximately $4 billion in vaccine-focused acquisitions (Curevo, LimmaTech Biologics, Vaccine Company) and genetic medicine expansion (Engage Biologics, Ajax, Kelonia, Centessa, Orna) positions Lilly for sustained long-term growth beyond GLP-1 franchise dependency. The restoration of CVS formulary access for Zepbound eliminates a significant competitive disadvantage, while Foundayo's early launch data showing 80% new-to-GLP-1 patients indicates minimal cannibalization risk. Medicare obesity drug coverage expansion anticipated later in 2026 provides additional volume catalyst for market penetration acceleration.

Thesis Status

The investment thesis has strengthened materially since the May 27th report. The CVS Caremark formulary restoration represents a critical validation of Zepbound's competitive positioning and directly addresses the market share erosion concern that emerged during the 2024-2026 exclusion period. This development, combined with the stock's approach to all-time highs and market cap recovery above $1 trillion, confirms investor confidence in the GLP-1 franchise durability. The company's aggressive M&A strategy totaling over $4 billion in vaccine acquisitions demonstrates management's commitment to portfolio diversification while maintaining GLP-1 market leadership. Foundayo's successful launch without significant cannibalization validates the oral formulation strategy and expands addressable market segments. The thesis remains intact with enhanced conviction given resolved formulary access challenges and demonstrated ability to sustain volume growth despite pricing headwinds.

Key Drivers

The primary catalyst driving recent performance is CVS Caremark's decision to restore Zepbound to its preferred formulary effective October 2026, reversing the 2024 exclusion that had enabled Novo Nordisk market share gains. Concurrently, Foundayo receives CVS coverage starting June 1st, providing immediate market access for the oral obesity medication. Strategic portfolio expansion continues with approximately $4 billion in vaccine-focused acquisitions (Curevo $1.5B, LimmaTech $780M, Vaccine Company $1.55B) and genetic medicine capabilities through Engage Biologics for up to $202 million. The company maintains shareholder returns with a $1.73 per share Q2 2026 dividend payable June 10th. Upcoming investor engagement includes Goldman Sachs Healthcare Conference participation on June 9th featuring cardiometabolic health leadership.

Technical Analysis

Eli Lilly exhibits strong bullish momentum with the stock trading at $1,126.80, just 0.4% below the May 28th intraday peak of $1,130.90. The recent breakout above $1,100 on heavy volume confirms institutional accumulation and establishes this level as critical near-term support. The one-day gain of +4.05% on the CVS news represents decisive buying pressure, while the five-day advance of +10.59% demonstrates sustained momentum rather than speculative spike. The stock has recovered fully from the April weakness, with the one-month gain of +28.92% representing a classic V-shaped reversal pattern. Resistance at the $1,131 all-time high appears vulnerable to imminent breakout given current momentum. Secondary support exists at $1,089 (May 27th close) and $1,067 (May 22nd close), creating a well-defined uptrend structure. The YTD gain of +4.85% understates recent momentum given the April drawdown, while the six-month performance of +4.77% reflects consolidation following the November 2025 peak before the current breakout phase.

Bull Case

• CVS formulary restoration eliminates competitive disadvantage: Zepbound returns to CVS Caremark's preferred drug list in October 2026, directly addressing market share losses to Novo Nordisk during the 2024-2026 exclusion period and providing access to CVS's extensive patient base for immediate volume recovery.
• Exceptional revenue growth with volume offsetting pricing pressure: Q1 2026 revenue reached $19.8 billion (+56% YoY) with 49% volume growth offsetting 7% pricing decline, demonstrating sustainable demand elasticity and market expansion capacity that validates continued investment in GLP-1 franchise despite government pricing agreements.
• Foundayo launch expands market without cannibalization: Over 20,000 patients initiated Foundayo with 80% being new to GLP-1 treatments, confirming the oral formulation addresses previously untapped patient segments while preserving injectable franchise value and expanding total addressable market.
• Strategic diversification through $4B+ acquisition pipeline: Vaccine acquisitions totaling approximately $4 billion combined with genetic medicine expansion through Engage Biologics and prior Ajax, Kelonia, Centessa, Orna deals establishes multiple growth vectors beyond GLP-1 dependency for long-term revenue diversification.
• Raised full-year guidance confirms momentum sustainability: 2025 revenue guidance increased to $82-85B (from $80-83B) and EPS to $35.50-37 (from $33.50-35) reflects management confidence in sustained demand trajectory and operational execution capability despite competitive and regulatory headwinds.

Bear Case

• Persistent pricing pressure from government agreements: 7% U.S. pricing decline in Q1 2026 due to Trump administration drug pricing agreement and ongoing competitive discounting creates margin compression risk that may accelerate if volume growth decelerates or competitive intensity increases.
• Safety concerns create regulatory and reputational risk: FDA reported one patient liver failure case with Foundayo, and despite company determination of no causal relationship, ongoing pharmacovigilance requirements and potential for additional adverse events could impact prescriber confidence and regulatory pathway for expansion.
• Delayed CVS coverage limits near-term Zepbound recovery: Zepbound formulary restoration delayed until October 2026 extends the competitive disadvantage period through peak summer season, allowing Novo Nordisk additional months to solidify patient relationships and potentially lock in market share through inertia.
• Significant M&A execution risk from $4B+ deployment: Three vaccine acquisitions totaling ~$4 billion plus multiple genetic medicine deals create substantial integration complexity and capital allocation risk if acquired platforms fail to deliver expected therapeutic advances or commercial returns.
• Valuation stretched at $1 trillion market cap: Market capitalization recovered above $1 trillion approaching all-time highs creates limited upside buffer if execution falters, with elevated valuation multiples vulnerable to earnings disappointment or competitive setbacks given high growth expectations embedded in current price.